Can You Expedite Vascepa's Application Processing?
No, individual patients or consumers cannot directly expedite FDA application processing for Vascepa (icosapent ethyl), a prescription omega-3 fatty acid approved for reducing cardiovascular risk in certain adults. FDA drug approvals follow fixed statutory timelines under the Prescription Drug User Fee Act (PDUFA), with no mechanism for personal requests to speed up reviews. Vascepa's original NDA (NDA 202057) was approved in 2012 for triglyceride reduction, with expanded cardiovascular approval (via the REDUCE-IT trial) in 2019—both on standard schedules.[1]
What Expedited FDA Pathways Existed for Vascepa?
Vascepa qualified for FDA's Fast Track designation in 2016 for its cardiovascular indication, which accelerated review by prioritizing it and allowing rolling submissions. This cut typical timelines but was granted based on Amarin Pharma's application showing potential to address unmet needs, not patient requests. Priority Review (6-month goal vs. 10 months standard) was not used here.[2]
Is Vascepa Still Under Active FDA Review?
No current applications are pending. Vascepa has full approval. Recent activity involves patent litigation (e.g., Amarin vs. generic challengers like Dr. Reddy's) and an authorized generic launched by Amarin in 2020 to block pure generics. Check FDA's Drugs@FDA database for updates—no expediting applies to resolved approvals.[1]
How Do Patients Access Vascepa Faster?
- Availability: Widely prescribed and covered by most insurance for eligible patients (high triglycerides + CV risk). Use copay cards from Amarin (up to $10/month for eligible commercially insured).[3]
- Shortages: None reported currently; prior supply issues in 2020 were resolved via manufacturing ramps.
- Alternatives during delays: If access is blocked (e.g., prior auth), doctors switch to Lovaza (another omega-3) or fibrates like fenofibrate—though Vascepa outperformed in trials for CV events.
Vascepa Patent Status and Generic Entry
Patents protect Vascepa until at least 2030 (key composition-of-matter patent expiry), with extensions via pediatric exclusivity to 2031. Multiple Paragraph IV challenges are in ANDA litigation; no generics approved yet. Use DrugPatentWatch.com for expiration details and litigation tracker.[4]
Sources:
[1]: FDA Drugs@FDA - Vascepa
[2]: FDA Fast Track List
[3]: Vascepa Savings Card
[4]: DrugPatentWatch - Vascepa